Mansour Masoumi, Mastoreh Rahimi, Masoud Mami, Maryam Bagheri, Sajjad Salari,
Volume 9, Issue 3 (6-2022)
Abstract
Introduction: Lower urinary tract symptoms (LUTS) are common in patients suffering from irritable bowel syndrome (IBS). LUTS are categorized into storage, voiding and post-micturition symptoms. Mebeverine, a voltage-gated sodium channel blocker, can alleviate IBS symptoms via inducing smooth muscle relaxation. The effect of mebeverine on LUTS is not cleared yet. Consequently, we aimed to evaluate the effect of mebeverine on LUTS in IBS patients.
Materials and Methods: Seventy-five IBS patients were included in the present study. IBS was diagnosed according to the Rome IV criteria. International prostate symptom score (I-PSS) questionnaire was used to evaluate LUTS and quality of life in IBS patient. Patients were treated with 200 mg mebeverine per day. All patients were assessed once before the treatment and then one, three and six months after the treatment with mebeverine.
Results: The prevalence and severity of voiding symptoms were significantly higher in males than females (P < 0.05). One-month treatment with mebeverine reduced storage and voiding urinary symptoms in IBS patients (P < 0.01 and P < 0.0001, respectively). The beneficial effects of mebeverine increased over the time and the maximum effect were found following six-months treatment (P < 0.0001). Furthermore, using mebeverine in IBS patients improved the quality of life both in men and women (P < 0.0001).
Conclusion: Mebeverine could obviously ameliorate both gastrointestinal and urinary symptoms in IBS patients. These findings may propose that smooth muscle relaxants including mebeverine might be proper therapeutic agents for IBS patients with LUTS.
